Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214272 · ClinicalTrials.gov registry record · NA
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
A NA study of Skin Resurfacing, sponsored by Bausch Health Americas.
- Active
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 5
- Study locations
NCT07214272: Active NA study of Skin Resurfacing, sponsored by Bausch Health Americas.
NCT07214272 is a NA study of Skin Resurfacing that is active but no longer recruiting, run by Bausch Health Americas. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214272, a NA study of Skin Resurfacing, is active but no longer recruiting, sponsored by Bausch Health Americas.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a prospective, post-marketing (Phase 4) non-registrational single-arm, open-label, multicenter study.
Primary Outcome
Proportion of participants with any improvement after 3 treatments as assessed by Investigator Global Aesthetic Improvement Scale (iGAIS) at End of Study
Conditions Studied
Interventions
- DEVICE Fraxel® FTX Laser System
Study Locations (5)
California
- Dermatology Cosmetic Laser Associates of La Jolla, Inc. d/b/a West Dermatology Research Center - La Jolla
Florida
- Miami Dermatology & Laser Research LLC - Miami
Illinois
- Oak Dermatology, LLC - Naperville
New York
- Union Square Laser Dermatology, P.C - New York
Texas
- Dermatology and Laser Surgery Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT07214272 still lists
NCT07214272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Skin Resurfacing appearing as the primary indexed condition, and to 1 intervention - of which Fraxel® FTX Laser System is the first listed.
NCT07214272 lists 5 locations in 5 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT07214272 about?
NCT07214272 is a clinical study titled "A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing". This study is a prospective, post-marketing (Phase 4) non-registrational single-arm, open-label, multicenter study.
What is the current status of trial NCT07214272?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 49 participants. The study started on 2025-10-17. Estimated completion is 2026-09.
What conditions does trial NCT07214272 study?
This clinical trial studies the following conditions: Skin Resurfacing.
What interventions are being tested in trial NCT07214272?
The interventions under investigation include: Fraxel® FTX Laser System (DEVICE).
Who is sponsoring clinical trial NCT07214272?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214272 being conducted?
This trial has 5 study locations across California, Florida, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07214272's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI